Deletion of gene A41L enhances vaccinia virus immunogenicity and vaccine efficacy
- PMID: 16361415
- DOI: 10.1099/vir.0.81417-0
Deletion of gene A41L enhances vaccinia virus immunogenicity and vaccine efficacy
Abstract
Vaccinia virus (VACV) is the vaccine that was used to eradicate smallpox and is being developed as a recombinant vaccine for other pathogens. Removal of genes encoding immunomodulatory proteins expressed by VACV may enhance virus immunogenicity and improve its potential as a vaccine. Protein A41 is a candidate for removal, having sequence similarity to the VACV chemokine-binding protein, vCKBP, and an association with reduced inflammation during dermal infection. Here, it is shown that, at low doses, VACV strain Western Reserve (WR) lacking A41L (vDeltaA41L) was slightly more virulent than wild-type and revertant controls after intranasal infection of BALB/c mice. The primary immune response to vDeltaA41L was marked by an increase in the percentage of VACV-specific gamma interferon-producing CD8(+) T cells and enhancement of cytotoxic T-cell responses in the spleen. However, this augmentation of cellular response was not seen in lung infiltrates. Splenic CD8(+) T-cell responses were also enhanced when VACV strain modified vaccinia virus Ankara (MVA) lacking A41L was used to immunize mice. Lastly, immunization with VACV MVA lacking A41L provided better protection than control viruses to subsequent challenge with a 300 LD(50) dose of VACV WR. This study provides insight into the immunomodulatory role of A41 and suggests that MVA lacking A41 may represent a more efficacious vaccine.
Similar articles
-
Vaccinia Virus: From Crude Smallpox Vaccines to Elaborate Viral Vector Vaccine Design.Biomedicines. 2021 Nov 26;9(12):1780. doi: 10.3390/biomedicines9121780. Biomedicines. 2021. PMID: 34944596 Free PMC article. Review.
-
Increased attenuation but decreased immunogenicity by deletion of multiple vaccinia virus immunomodulators.Vaccine. 2016 Sep 14;34(40):4827-34. doi: 10.1016/j.vaccine.2016.08.002. Epub 2016 Aug 17. Vaccine. 2016. PMID: 27544585 Free PMC article.
-
Modified Vaccinia Virus Ankara Can Induce Optimal CD8+ T Cell Responses to Directly Primed Antigens Depending on Vaccine Design.J Virol. 2019 Oct 15;93(21):e01154-19. doi: 10.1128/JVI.01154-19. Print 2019 Nov 1. J Virol. 2019. PMID: 31375596 Free PMC article.
-
Deletion of the vaccinia virus N2L gene encoding an inhibitor of IRF3 improves the immunogenicity of modified vaccinia virus Ankara expressing HIV-1 antigens.J Virol. 2014 Mar;88(6):3392-410. doi: 10.1128/JVI.02723-13. Epub 2014 Jan 3. J Virol. 2014. PMID: 24390336 Free PMC article.
-
Modified Vaccinia virus Ankara: innate immune activation and induction of cellular signalling.Vaccine. 2013 Sep 6;31(39):4231-4. doi: 10.1016/j.vaccine.2013.03.017. Epub 2013 Mar 21. Vaccine. 2013. PMID: 23523404 Review.
Cited by
-
Vaccinia Virus: From Crude Smallpox Vaccines to Elaborate Viral Vector Vaccine Design.Biomedicines. 2021 Nov 26;9(12):1780. doi: 10.3390/biomedicines9121780. Biomedicines. 2021. PMID: 34944596 Free PMC article. Review.
-
Rapid poxvirus engineering using CRISPR/Cas9 as a selection tool.Commun Biol. 2020 Nov 3;3(1):643. doi: 10.1038/s42003-020-01374-6. Commun Biol. 2020. PMID: 33144673 Free PMC article.
-
Genes that Control Vaccinia Virus Immunogenicity.Acta Naturae. 2020 Jan-Mar;12(1):33-41. doi: 10.32607/actanaturae.10935. Acta Naturae. 2020. PMID: 32477596 Free PMC article.
-
Vaccinia virus-mediated cancer immunotherapy: cancer vaccines and oncolytics.J Immunother Cancer. 2019 Jan 9;7(1):6. doi: 10.1186/s40425-018-0495-7. J Immunother Cancer. 2019. PMID: 30626434 Free PMC article. Review.
-
A System Based-Approach to Examine Cytokine Response in Poxvirus-Infected Macrophages.Viruses. 2018 Dec 5;10(12):692. doi: 10.3390/v10120692. Viruses. 2018. PMID: 30563103 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials